Jury deliberations begin in lawsuit filed by Virginia teacher shot by 6-year-old student Ryan Murphy’s ‘All's Fair’ gets ...

Doctors say some fevers don't need to be treated, but insist there's no need to fear the commonly used pain reliever.

On "The Final 5," former CDC Director Dr. Tom Frieden, author of the new book "The Formula for Better Health," urged viewers ...

Kimberly-Clark Corporation (NASDAQ: KMB) is one of the stocks Jim Cramer recently commented on. Cramer highlighted the ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

When the president doesn’t feel well or has a medical problem. I wonder if he reaches out to his doctor and medical staff or ...

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer ...

Personal healthcare products provider Kenvue Inc. (NYSE:KVUE) has been in the news for one reason or another recently.

A month after claiming a link between Tylenol use and autism, Health Secretary Robert F. Kennedy Jr. now says there's 'not ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?